CTi Biopharma Corp (NASDAQ:CTIC)

1.71
Delayed Data
As of May 22
 -0.03 / -1.72%
Today’s Change
1.69
Today|||52-Week Range
3.23
-27.54%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$313.6M

Company Description

CTI BioPharma Corp. operates as a biopharmaceutical company, which is focused on the acquisition, development, and commercialization of less toxic and more effective ways to treat cancer. Its products include Pixuvri, OPAXIO, Brostallicin and Bisplatinates. Pixuvri is a novel anthracycline derivative used for the treatment of hematologic malignancies and solid tumors. The company was founded by James A. Bianco, Jack W. Singer and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Contact Information

CTI BioPharma Corp.
3101 Western Avenue
Seattle Washington 98121
P:(206) 282-7100
Investor Relations:
(206) 272-4343

Employees

Shareholders

Individual stakeholders3.49%
Mutual fund holders21.74%
Other institutional13.36%

Top Executives

James A. BiancoPresident, Chief Executive Officer & Director
Lou A. BiancoExecutive Vice President-Finance & Administration
Jack W. SingerDirector & EVP-Global Medical Affairs
Matthew J. PlunkettExecutive Vice President-Corporate Development
Monique GreerSVP-Investor Relations & Corporate Communications

To view my watchlist

Not a member yet?

Sign up now for a free account